Research Synthesis: Aerobic exercise

Research Synthesis: Aerobic exercise

Abstract

Evidence-honesty note: 17/33 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on Aerobic exercise across 33 included source papers and 2116 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 20 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 179 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the muscle function, contextual adjacent evidence and cardiometabolic outcome classes, null signals in the contextual adjacent evidence, cardiometabolic and muscle function outcome classes, and negative signals in the cardiometabolic outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that Aerobic exercise should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain is not automatically consistent with the same signal in another.

Introduction

Population aging has re-ordered the strategic priorities of clinical research, and with it the questions that healthspan-oriented trials are now expected to answer. By the late 2020s, the demographic pressure to extend the years spent in good health, rather than the years spent alive but disabled, has become impossible to separate from any serious cardiometabolic, neurocognitive, or musculoskeletal research agenda. The question of whether readily deployable interventions can modify the trajectory of aging biology, rather than waiting for individual chronic diseases to declare themselves, has accordingly moved from a fringe concern to a central organizing question for translational medicine. The present synthesis is anchored to that question, and to a specific candidate: Aerobic exercise, understood here as the structured, repetitive, sustained-moderate-to-vigorous activity that has occupied a near-monopoly position in physical-activity guidelines since the WHO 2000 bulletin on physical activity and sedentary behaviour (Bull 2020). The clinical stakes are high, the public-health infrastructure for delivery is already in place, and the regulatory history of Aerobic exercise is unlike that of any candidate pharmacologic — it is a behavior that can be prescribed, monitored, and adapted without a marketing authorization, and yet it is evaluated with methods borrowed directly from drug-development pipelines. That juxtaposition, the oldest non-pharmacologic intervention in the field being asked to satisfy the evidentiary expectations of a modern geroscience trial, is the practical reason this synthesis is needed now.

The geroscience hypothesis offers a useful lens on why Aerobic exercise has become a recurring reference point in this debate. The hypothesis holds that interventions targeting the upstream biology of aging, rather than any single downstream disease, may yield larger and more durable effects on multimorbidity than disease-by-disease treatment strategies, and it has been operationalized most visibly in trials of candidate geroprotectors such as metformin, rapalogs, and senolytics. Within that framework, Aerobic exercise is interesting precisely because it does not fit cleanly into the repurposed-molecule or novel-development categories: it is a non-pharmacologic, behaviorally mediated stimulus with systemic effects on mitochondrial biogenesis, insulin signaling, low-grade inflammation, and vascular endothelial function, all pathways that drug candidates in the geroscience pipeline are also trying to engage. The intervention logic, in other words, converges: the question of whether Aerobic exercise modifies aging biology shares endpoints, surrogate markers, and mechanistic language with the question of whether metformin or any rapalog does so, and the field has been increasingly willing to hold Aerobic exercise to the same evidentiary standards. But there is an important asymmetry, namely that Aerobic exercise has no patent, no phase I/II/III roadmap, and no commercial sponsor with an interest in funding the long, hard-outcome trials that the geroscience community has so far largely failed to deliver for any candidate. The result is an evidence base that is dense with short-term surrogate-endpoint trials, sparse on hard clinical outcomes, and organized, when it is organized at all, around the conventions of sports medicine rather than those of aging research.

Several unresolved questions prevent any simple endorsement of Aerobic exercise as a geroscience intervention, and the sources themselves make those questions visible. The second concerns tradeoffs: a 12-week post-exercise hot-water immersion adjunct produced additional haemodynamic and vascular benefits in physically inactive middle-aged adults (mean age 58 ± 5 years, BMI 28 ± 3 kg/m²) but did not further improve cardiorespiratory fitness, glucose, lipids, or inflammation (Steward 2025), suggesting that added components may shift benefit distribution rather than amplify it. The third concerns population specificity, as outcomes in type 2 diabetes (OConnor 2025), obesity (Elsayed 2023, Jayedi 2024), COPD (Latimer 2022), and early Alzheimer's (Morris 2017) appear to vary with baseline comorbidity in ways that aggregated meta-analyses obscure. The fifth concerns dose-response itself, with the American College of Sports Medicine framework cited by Jayedi 2024 implying nonlinear effects of Aerobic exercise on weight loss that the available trials are not powered to resolve.

The contribution of this synthesis is to take the apparently simple question, does Aerobic exercise modify aging-relevant outcomes, and to decompose it into the smaller, more answerable questions that the sources can actually bear. The synthesis proceeds by weighting evidence at the level of outcome class rather than study, by separating clinical-outcome reports from mechanistic-surrogate reports, and by treating population specificity as a first-class variable rather than a nuisance term. It also explicitly refuses to assert that Aerobic exercise extends lifespan, prevents cognitive decline, or reverses multimorbidity on the basis of the present sources, framing the field's central question as the question of whether, for whom, and at what dose Aerobic exercise produces clinically meaningful gains on hard endpoints rather than surrogate ones, the kind of question for which the available evidence remains, at best, suggestive. The synthesis that follows is therefore structured as a weighted, tension-aware reading of the sources, not as a vote count, and its central claim is that the Aerobic exercise anti-aging case is mechanistically plausible and directionally favorable in some outcome classes, but is incomplete as currently constituted, and that the missing pieces are empirical rather than rhetorical.

Background

Geroscience reframes aging as a coordinated set of interdependent biological mechanisms — the so-called hallmarks of aging — rather than as the passive accumulation of unrelated deficits, and this conceptual shift has direct regulatory and therapeutic implications for interventions such as aerobic exercise. Within this framing, candidate geroprotectors are evaluated not solely by their capacity to delay a single age-related disease but by their demonstrable engagement with several mechanistic axes, including mitochondrial bioenergetics, proteostasis, stem-cell function, cellular senescence, and inflammation. Aerobic exercise has been proposed as a prototypical geroprotector precisely because it appears to perturb multiple hallmarks simultaneously, raising the possibility that structured physical activity could serve as a low-cost, scalable modulator of the biology of aging rather than a narrow treatment for any one chronic condition. At the same time, the geroscience framework imposes a stricter evidentiary burden: improvements in surrogate biomarkers are not treated as sufficient, and the field is increasingly attentive to the gap between mechanistic plausibility and hard clinical outcomes. This higher bar is relevant to the aerobic exercise literature, which is large in volume but heterogeneous in design, with intervention durations, populations, and endpoints varying widely across trials. For the present synthesis, the aerobic exercise case is therefore framed as a context-dependent one: biologically motivated, clinically tested, and methodologically incomplete, with boundary conditions that have yet to be fully defined.

At the preclinical and disease-model level, aerobic exercise is associated with a coherent set of physiological adaptations that map onto geroscience-relevant pathways, although the source-level evidence for any single mechanism is uneven. Mitochondrial remodeling has been documented in human skeletal muscle, where short-term cycling protocols produced reproducible transcript and protein-level adaptations in oxidative-phosphorylation machinery (Egan 2013), and similar mitochondrial responses have been observed in patient populations such as those with chronic obstructive pulmonary disease, where the maximal aerobic power per mitochondrion can be partially restored by training (Latimer 2022). Vascular mechanisms have been investigated using animal models of vascular aging, in which moderate-intensity aerobic exercise modulated nitric-oxide-dependent vasorelaxation and adropin signalling (Fujie 2021), and an exploratory histological study compared aerobic exercise against an alternative vascular-aging intervention in rats (Damay 2023). Translational relevance to humans remains uncertain. Cardiometabolic mechanisms have been examined in obese older adults, where combined exercise and phototherapy shifted hemostasis markers resistant to hypercoagulability (Elsayed 2023). However, not all mechanistic effects observed in disease models translate cleanly: in middle-aged inactive adults, adding post-exercise hot-water immersion enhanced some hemodynamic and vascular responses without producing additional improvements in cardiorespiratory fitness, glucose, lipids, or systemic inflammation (Steward 2025), illustrating that physiological signals sensitive to one manipulation may remain unchanged for adjacent endpoints. The cumulative picture from the preclinical and disease-model literature is therefore that aerobic exercise engages several plausibly geroprotective axes, but that effect direction and magnitude are endpoint-specific, an observation that carries forward into the human evidence base.

Several methodological questions recur across the aerobic exercise literature and constrain the strength with which clinical recommendations can currently be made. First, the endpoints most often reported are surrogate or intermediate outcomes — flow-mediated dilation, V̇O2peak, body-fat percentage, telomere length, cognitive composite scores — rather than hard clinical events, and the methodological caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005) applies directly to this evidence base. Second, intervention duration varies dramatically, from eight-week protocols (Hinchman 2022; Tanaka 2012) to twelve-month follow-ups (Voss 2010), and the trial-level signal sometimes emerges only at the longer timepoints, complicating dose-response inference. Third, comparator arms differ widely, ranging from non-exercise or stretching controls to active comparators such as phototherapy (Elsayed 2023), pioglitazone (OConnor 2025), or electronic cigarette exposure in animal work (Damay 2023), which limits cross-study comparability. Fourth, the literature includes both mechanistic and clinical outcomes within the same outcome classes, producing the tension patterns observed in the synthesis — for example, positive muscle-function signals in trials of glucose-intolerant or multimorbid adults (Baker 2010; Lo 2021) coexist with null or mixed signals in broader reviews of combination training (Bai 2022) and in longer-duration cognitive trials (Voss 2010; Hinchman 2022). Finally, concurrent interventions such as individualized programming, behavioral engagement, or adjunctive brain stimulation are common, raising the question of whether reported effects should be attributed to aerobic exercise per se or to the package in which it is delivered (Hinchman 2022; Thomas 2021; Lo 2021). Until these methodological questions are addressed through more standardized endpoints, longer follow-up, and more consistent comparator design, the aerobic exercise case as a geroprotector will continue to be characterized by mechanistic promise coexisting with mixed human-RCT evidence and unsettled boundary conditions.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-aerobic_exercise-v06-DAILY-2026-06-09T22-52-16Z-R2.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-09.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• aerobic exercise AND aging AND randomized trial
• endurance training AND older adults AND cognition
• walking program AND elderly AND frailty
• cardiorespiratory fitness AND mortality AND cohort
• aerobic exercise AND VO2max AND older adults

Eligibility criteria

• Sources whose primary content addresses aerobic exercise.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 759 records in the receipt-candidate union, 207 were classified as source candidates and 33 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	759
Classified source candidates	207
No extractable claims	134
None-only claim binding	59
Mixed partial-or-none claim-binding candidates	228
Partial-only claim-binding candidates	92
Strict high-confidence sources	39
Admitted final sources	33

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, muscle function, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=18; claims=1101	no extracted directional signal in 11/18 sources	13 indirect; 5 review	limited corpus depth in this outcome class
Muscle Function	n=9; claims=597	positive signal in 3/9 sources	2 indirect; 7 review	limited corpus depth in this outcome class
Cardiometabolic	n=4; claims=338	no extracted directional signal in 2/4 sources	3 indirect; 1 review	limited corpus depth in this outcome class
Dosing and Pharmacokinetics	n=1; claims=13	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Skeletal, Fracture, and Bone	n=1; claims=67	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Cardiometabolic Outcomes

Four curated references populate the cardiometabolic outcome class. Huang 2025 contributed a systematic review and network meta-analysis in sedentary adults with no enrolled clinical population, comparing modalities for body-fat and cardiorespiratory endpoints.

Quantitative findings diverge by design and population. No source-traced p-values were available in Donath 2017.

Mechanistically, the three clinical or quasi-clinical sources speak to overlapping but non-identical cardiometabolic pathways. Steward 2025 isolates vascular and haemodynamic reactivity as the substrate responsive to thermal augmentation, leaving the canonical cardiometabolic risk markers (glucose, lipids, inflammation, fitness) unchanged beyond exercise itself. Elsayed 2023 implicates the coagulation-fibrinolysis axis, with laser phototherapy modulating hypercoagulability markers in obese seniors. Huang 2025 mechanistically grounds the body-fat signal in modality-specific energy expenditure and substrate utilization, where aerobic training exceeds resistance and combined regimens in sedentary adults. Preclinical and mechanistic data therefore support multiple distinct biological handles, while the human clinical RCT-level evidence for any single handle remains narrow.

Within-corpus tensions are most visible in the cardiometabolic class. Steward 2025 and Donath 2017 (severity 3) also disagree on whether adjunctive stimuli shift cardiometabolic status, with Donath 2017 finding no cardiometabolic perturbation from acute aerobic exercise. Together these tensions suggest that the cardiometabolic case for aerobic exercise is boundary-condition-dependent, modulated by population (sedentary vs active, obese vs normal-weight), modality (aerobic alone vs aerobic + heat or phototherapy), and endpoint class (vascular reactivity vs coagulation vs body composition).

Contextual Adjacent Evidence Outcomes

Eighteen of the curated sources populate the contextual/mixed outcome class, and together they paint a heterogeneous picture that resists a single net-direction summary. These three sources anchor the contextual/mixed class with human-RCT or systematic-review evidence and supply the high-density numeric spine of this subsection (see the evidence synthesis for the full per-study p-value inventory).

The vascular-endothelial and arterial-stiffness sub-thread is dominated by null or directionally mixed findings despite robust continuous-aerobic RCT inputs. When read alongside Bull 2020, which articulates WHO 2000 physical-activity guidance rather than a primary endpoint, the vascular thread shows that statistical superiority versus sedentary comparators does not automatically translate into a positive verdict against active comparators — a recurrent pattern across the contextual/mixed class (Bull 2020; Tao 2023; You 2022).

Mechanistically, the cognitive and brain-network subliterature populates the same outcome class but with three additional mechanism-level sources. The mechanistic substrate underlying these functional findings is plausibly tied to endothelial-NO signaling (Fujie 2021), to cerebrovascular reserve (Bliss 2023), and to cardiorespiratory-fitness adaptations (Tsuji 2023), but the contextual/mixed class does not localize any single pathway as the dominant mediator of the cognitive signal.

Dosing and Pharmacokinetics Outcomes

Salisbury 2023 is the only corpus study mapped to the dosing/pharmacokinetics outcome class for aerobic exercise, and it is positioned as an indirect observational cohort in adults rather than a clinical RCT [Salisbury 2023]. The study correlated changes in cardiorespiratory fitness (CRF) with resting plasma neurotrophic factors in the setting of Alzheimer's dementia, treating the exercise dose–response relationship as a biomarker-mapping exercise rather than a pharmacokinetic clearance study [Salisbury 2023]. The endpoint of interest is therefore the correspondence between training-dose surrogates and downstream neurotrophic signaling, not drug-style absorption or distribution [Salisbury 2023]. The synthesis classifies this evidence as indirect because the dosing construct is operationalized through change-in-CRF rather than a quantified exercise prescription [Salisbury 2023].

No direction of effect could be extracted, and the source's effect direction field is null, which the analysis treats as evidence against a robust monotonic dose–response signal in this particular study [Salisbury 2023]. The reported p-values can be interpreted as descriptive of a single indirect observational cohort and not as a pooled dose–response estimate [Salisbury 2023].

Mechanistically, the mechanistic substrate underlying this null finding would normally invoke exercise-induced neurotrophin release, yet Salisbury 2023 found no detectable correspondence between CRF change and plasma neurotrophic factors, suggesting either that resting peripheral neurotrophins are insensitive to aerobic dose in Alzheimer's dementia or that the dosing construct itself was too loosely operationalized to detect an effect [Salisbury 2023]. Because the source carries directness = indirect and the design is observational, the study is better framed as hypothesis-generating for a future clinical RCT than as confirmatory mechanistic human data [Salisbury 2023].

Within the corpus there is no second dosing/pharmacokinetics study to triangulate Salisbury 2023, so no within-corpus tension can be named in this outcome class, and the brief's broader cross-class signal of null findings dominating contextual-other and cardiometabolic endpoints is consistent with — but not directly tested against — this single indirect cohort [Salisbury 2023]. Together these clinical RCT and cohort designs establish the trial summary for the muscle-function class: aerobic interventions of 8 weeks to several months, adult and older-adult populations, and physical-fitness or cardiorespiratory endpoints.

Skeletal, Fracture, and Bone Outcomes

Egan 2013 is the single curated human-physiology study contributing to the skeletal, fracture, and bone outcome class, and it is positioned as indirect rather than direct evidence because its primary endpoint is molecular kinetics in skeletal muscle rather than a clinical fracture or bone-density outcome. The study is observational in design with a short, fixed exposure window and a very small cohort, which limits inferential strength for skeletal endpoints. No fracture incidence, bone mineral density, or surrogate imaging endpoint is reported; the only directness-relevant signal is that adaptation was measured in skeletal muscle tissue, not in bone. Readers should therefore treat any inference about bone outcomes from this source as exploratory rather than confirmatory.

Because these statistics index molecular adaptation in muscle, the relevant numerator is the number of gene/protein endpoints reaching P < 0.05 within the curated set, not a clinical fracture or bone-density effect size; the source does not provide a hazard ratio, odds ratio, or relative risk for any bone endpoint. No 95% confidence intervals are reported in the curated excerpt, and the source does not state a primary analytic endpoint. Effect direction is recorded as null for the skeletal fracture bone class because the molecular findings, while positive in muscle, do not translate within the source to a directional bone outcome.

Mechanistically, the Egan 2013 substrate is a short-term aerobic-exercise challenge in healthy sedentary adults, with molecular readouts in skeletal muscle; it is therefore best characterized as a mechanistic human study rather than a clinical RCT, and its applicability to skeletal fracture bone endpoints requires an inferential bridge from muscle adaptation to bone remodeling. That bridge is not made within the curated source, and the source itself does not assert any bone-relevant mechanism. In a broader anti-aging framework, an aerobic stimulus that drives repeatable transcript and protein responses in muscle (P < 0.05 across multiple gene/protein endpoints) is biologically plausible as a modifier of mechanotransductive loading on bone, but plausibility is not evidence and no bone endpoint is measured. The within-corpus record for this outcome class is therefore mechanistic-muscle data tagged to a skeletal outcome label, with directness acknowledged as indirect.

Within-corpus tension for the skeletal fracture bone class is minimal because Egan 2013 is the sole curated source in this outcome class and there are no non-orthogonal same-outcome pairs in the cross-study disagreement map to contrast against it. Readers comparing this outcome class against the broader synthesis should note that any apparent contradiction is a labeling artifact rather than a disagreement between studies. Consequently, the honest summary for this subsection is that the curated evidence base for skeletal, fracture, and bone outcomes in the Aerobic exercise literature is sparse, indirect, and not yet anchored by a clinical bone endpoint.

Muscle Function Outcomes

Quantitative findings cluster on the positive side of the effect-direction ledger for several entries but include a substantial block of null or unclear verdicts. Baker 2010 reported that six months of aerobic exercise improved executive function (MANCOVA, P = 0.04), cardiorespiratory fitness (MANOVA, P = 0.03), and insulin sensitivity (P = 0.05) in older adults with glucose intolerance. By contrast, Bai 2022 was tagged null at the review level, and Weber 2024 carried a mixed effect direction with P < 0.01, P = 0.016, P < 0.05, P < 0.001, P = 0.003, and P = 0.048 distributed across female-cognition sub-domains. The per-study p-value matrix is consolidated in the evidence synthesis (Per-Study Endpoint Evidence), which the prose here references rather than restates.

Mechanistically, the muscle-function improvements reported in the clinical RCT and cohort entries map onto the corpus's cardiorespiratory-fitness and inhibitory-control pathways, whereas the systematic-review entries aggregate mechanistic and human data and report a more heterogeneous picture. Schellnegger 2022 notes that eight included RCTs showed inconsistent findings of increased telomere length with physical activity in selected subpopulations, framing the biological substrate for muscle-function effects as population-conditional. Angevaren 2008 reported that eight of eleven included studies showed aerobic-exercise-induced increases in cardiorespiratory fitness in the intervention group, but the review-level effect direction on cognitive function was tagged unclear. The mechanistic substrate underlying the positive findings in Lo 2021, Baker 2010, and Li 2025 therefore rests on changes in cardiorespiratory fitness and downstream neural and metabolic pathways, with the human evidence strongest when adherence and individualized dosing are present.

Within-corpus tensions are dense in this outcome class and are best read as population-, endpoint-, and design-level disagreements rather than a single directional disagreement. Angevaren 2008 (unclear) disagrees with Weber 2024 (mixed), with Hinchman 2022 (mixed), and indirectly with the positive clinical RCT signals of Baker 2010 and Lo 2021. Baker 2010 (positive) sits in null-vs-positive tension with Dhahbi 2025 (null) and Bai 2022 (null), and in directional disagreement with Weber 2024 (mixed) and Hinchman 2022 (mixed). Lo 2021 (positive) and Li 2025 (positive) are mutually concordant and concordant with Baker 2010, but both are in null-vs-positive tension with Bai 2022 (null) and Dhahbi 2025 (null), and in directional disagreement with Hinchman 2022 (mixed) and Weber 2024 (mixed). Weber 2024 (mixed) and Hinchman 2022 (mixed) are the only two primary entries that align with each other, leaving the muscle-function class polarized between positive primary trials and null or unclear aggregated reviews — a pattern consistent with the brief's integrating thesis that mechanistic plausibility coexists with mixed or sparse human-RCT evidence and that boundary conditions remain to be established.

Muscle Function remains a separate Results slice (n=9; claims=597; positive signal in 3/9 sources; 2 indirect; 7 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.

Cross-Domain Synthesis

The first load-bearing cross-domain tension is between positive functional/behavioral muscle outcomes reported in supervised aerobic training trials and the largely null or mixed mechanistic/biomarker evidence sitting in the same body of literature. On one side, individualized aerobic exercise in middle-aged and older adults with multimorbidity produced positive physical-activity and health-related fitness changes (Lo 2021), and aerobic training improved executive function, cardiorespiratory fitness, and insulin sensitivity in glucose-intolerant older adults (Baker 2010). On the other side, a narrative review of aerobic, resistance, and combined training concluded that the net effect of aerobic-only exercise on counteracting age-related cognitive decline is null on average (Dhahbi 2025), and a systematic review of combination interventions in the elderly graded the aerobic evidence as null for several performance endpoints (Bai 2022). The most plausible mechanistic boundary is exercise dose and population risk: the positive Lo 2021 and Baker 2010 signals come from individualized or higher-risk samples (multimorbidity, glucose intolerance) where functional reserve is most limiting, whereas the null reviews pool heterogeneous programs across healthier older adults, diluting the signal. What would resolve the tension is harmonized reporting of attendance, intensity, and baseline frailty status, so that the positive functional findings (Lo 2021, Baker 2010) and the null pooled estimates (Dhahbi 2025, Bai 2022) are not compared across incommensurable designs.

At the mechanism level, this is a stacking-of-effects problem: Steward 2025's negative result reflects that adding post-exercise hot-water immersion on top of aerobic exercise enhances haemodynamic and vascular benefits but does not further improve cardiorespiratory fitness, glucose, lipids, or inflammation, meaning the exercise main effect was already partly absorbed by the co-intervention in the design. Elsayed 2023's positive result, by contrast, is a synergistic combination (exercise plus laser phototherapy) in a metabolically abnormal population, where the baseline hypercoagulable state gives the intervention more room to move. Huang 2025's null pooled effect across sedentary adults is consistent with both: when diverse trials are aggregated, the conditional synergy is lost and the average cardiometabolic delta shrinks. The boundary condition that best reconciles the three is population risk stratum combined with comparator intensity — obese/dysmetabolic samples (Elsayed 2023) show benefits, healthy inactive samples show no detectable lipid or glucose change beyond what the meta-analytic mean captures, and any added non-exercise modality (heat, laser) reshuffles which subsystem carries the gain. To resolve this, future trials should pre-specify cardiometabolic strata and report whether the comparator is true no-exercise control or an already-active comparator, since the Steward 2025 result is intelligible only against the active-control backdrop.

Another tension concerns the cerebrovascular/cognitive and neuroplasticity outcome cluster, where individual trials report positive or mixed effects (Bliss 2023, Morris 2017, Hinchman 2022) but the systematic-review layer is dominated by null syntheses (Voss 2010, Ezzdine 2025, You 2022, Tao 2023). At the synthesis level, Voss 2010 observed significant effects on brain networks only at 12 months and not at 6 months in older adults, Ezzdine 2025 reviews the literature as net null on neuroplasticity markers, and You 2022 finds null effects of aerobic exercise on vascular endothelial function in middle-aged and elderly subjects across multiple intensity strata. The mechanism-level explanation is that aerobic exercise modulates perfusion and network-level connectivity on a slower timescale than the typical 6- to 12-week trial window, which is why Bliss 2023's cross-sectional cerebrovascular contrast and Voss 2010's 12-month effects both surface positive signals while shorter mechanistic windows return null. The dissonance between surrogate cerebrovascular reactivity gains (Bliss 2023) and the null hard-cognition syntheses is itself a classic surrogate-vs-hard-outcome caution (Ioannidis 2005), in that improved reactivity is not equivalent to improved clinical cognition. To resolve the tension, the field needs trials that pair surrogate perfusion and connectivity outcomes with hard cognitive endpoints over ≥12 months, and that pre-stratify by baseline cerebrovascular reserve, which the current corpus does not provide.

Another tension — and the one most directly relevant to the anti-aging thesis — is between the mechanistic/biomarker plausibility literature and the human RCT evidence for hard functional endpoints, particularly in the domains of telomere maintenance, weight loss, and home-based cardiorespiratory adaptation. Schellnegger 2022's systematic review of physical activity and telomere length reports inconsistent findings across 8 RCTs, with no robust direction of effect, despite a clear observational signal in physically active adults. At the mechanism level, this is the familiar surrogate-vs-hard-outcome pattern: mechanistic biomarkers (FMD, telomere length, mtDNA copy number in Latimer 2022) shift under aerobic training, but these shifts are necessary but not sufficient for downstream functional and longevity benefit (Ioannidis 2005). The boundary condition that best explains the dispersion is the comparator: effects versus truly sedentary controls are positive and clinically meaningful (Tsuji 2023 vs non-exercise, Latimer 2022 positive on mitochondrial outcomes), but effects versus active comparators or in already-active adults (Salisbury 2023's null neurotrophic-factor correlations, the null arms of You 2022, Thomas 2021) are null. What would resolve the tension is a body of trials that simultaneously report biomarker change and a hard clinical endpoint (mobility, hospitalization, mortality) over durations that match the long preclinical timescales on which mechanistic plausibility is built; without that, the aerobic-exercise anti-aging case remains split between mechanistic promise and mixed or null human functional RCT evidence, as flagged by the picked thesis.## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Aerobic exercise produces consistent, source-anchored short-term improvements in cardiorespiratory fitness and selected vascular/cognitive intermediate phenotypes, but the corpus does not support durable anti-aging claims in older adults because the strongest hard-outcome signals are sparse, indirect, or null once surrogate endpoints are discounted (Ioannidis 2005). We interpret the corpus as best read as a mechanistic plausibility case layered over a human-RCT base that is dominated by intermediate endpoints, short follow-up, and heterogeneous effect directions across the cross-study disagreements surfaced in the matrix. The synthesis therefore takes the defensible middle position that the anti-aging case for aerobic exercise is mechanism-rich but outcome-thin, and that the boundary conditions separating responders from non-responders remain to be established.

The Bliss 2023 cerebrovascular signal is one of the most numerically robust findings in the entire corpus, and yet the cognitive/connectivity endpoints in Voss 2010, Dorsman 2020, and Hinchman 2022 do not consistently show that aerobic exercise translates the vascular gain into a hard cognitive or behavioural endpoint.

What the evidence supports clearly is a convergent mechanistic and intermediate-endpoint package. Translational relevance to humans remains uncertain. The mixed Li 2025 / Hinchman 2022 cognitive findings sit alongside this. We interpret this convergent intermediate-endpoint signal as the load-bearing reason the thesis is defensible: the mechanism is real, the dose–response is plausible, and the effect sizes in selected vascular and CRF outcomes are clinically meaningful. The translation to hard anti-aging endpoints, however, is not established, and the corpus suggests — but does not prove — that boundary conditions of age, baseline CRF, and adherence separate responders from non-responders.

Evidence Summary

The evidence base for this synthesis comprises 33 included sources. The evidence-tier distribution is: B2 (n=29), B1 (n=4). By directness, the breakdown is: indirect (n=20), review (n=13). 24 of 33 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: adults; type 2 diabetes patients; older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus does not contain any large, long-duration randomized controlled trial of aerobic exercise powered for hard clinical endpoints such as incident falls, fractures, disability, or all-cause mortality. As a result, every claim the synthesis makes about aerobic exercise as an anti-aging intervention is necessarily indirect, resting on surrogate and mechanistic readouts rather than on the hard-outcome evidence that would be required to settle clinical policy. The headline directionality in the cardiometabolic domain (e.g. Steward 2025 negative, Elsayed 2023 positive) is therefore unanchored to any mortality or major-adverse-event trial within the corpus.

Several clinically important outcomes are touched by only a single source in the corpus, which makes them unreplicable from within the curated evidence and highly sensitive to that one study's design. For example, OConnor 2025 is the only source addressing aerobic training in type 2 diabetes, Elnaggar 2026 is the only pediatric-leukemia-survivor RCT, Damay 2023 is the only animal histological study, and Li 2025 is the only incarcerated-substance-dependence trial. Where the cross-study disagreement map flags a null-vs-positive or null-vs-unclear disagreement, it frequently does so because the positive arm is in fact that lone source.

The enrolled populations skew toward narrow subgroups whose external validity is bounded in identifiable ways. Healthy sedentary middle-aged adults dominate (e.g. Egan 2013 in 8 healthy sedentary males; Tanaka 2012 in healthy young subjects; Hinchman 2022 in sedentary adults at risk of cognitive decline), with selected older-adult (Baker 2010; Lo 2021; Bliss 2023) and obesity samples (Elsayed 2023, mean BMI 34.55 ± 2.67 kg/m²; Steward 2025, mean BMI 28 ± 3 kg/m²) representing the main clinical extensions. The synthesis therefore cannot speak to the population for whom anti-aging claims are most often invoked.

The endpoint scope of the corpus is narrow. They do not report hard functional outcomes such as gait-speed change, which prevents benchmarking against the Perera 2006 0.1 m/s substantial-improvement threshold or the 0.05 m/s annual age-related decline rate (Bohannon 1997). The Ioannidis 2005 caution that surrogate associations do not guarantee hard-outcome validity applies directly: the entire synthesis is built on surrogates, with no within-corpus mechanism to escalate them to clinical endpoints.

Finally, the mechanism-to-clinic gap is pronounced. Mechanistic and animal-model evidence is present (Damay 2023 in Wistar rats; Fujie 2021 in mature adult rodents; Egan 2013 in human skeletal-muscle gene-expression kinetics; Schellnegger 2022 on telomere biology), but the leap from those mechanistic signals to a clinically actionable anti-aging recommendation in humans is unsupported within the corpus. Schellnegger 2022 itself reports inconsistent telomere-length findings across only n = 8 RCTs, and the cross-cross-study disagreement map shows that mechanistic plausibility for muscle-function outcomes (Baker 2010 positive) is contradicted by null summary evidence (Bai 2022; Dhahbi 2025) and by mixed scoping reviews (Weber 2024). The corpus therefore cannot adjudicate whether the mechanistic case for aerobic exercise translates into measurable clinical anti-aging benefit, and any headline conclusion of the synthesis must be qualified accordingly.

Conclusion

Across the corpus, this synthesis positions Aerobic exercise as a biologically plausible but empirically incomplete candidate geroprotective intervention, whose effect direction varies by outcome class rather than uniformly favoring benefit. Across 33 curated references, the body of work appears to support a hypothesis that aerobic training can favorably modulate discrete muscle-function and cerebrovascular endpoints in selected older-adult populations, while broader claims regarding cardiometabolic, vascular-aging, telomere, and neurocognitive endpoints remain to be confirmed in adequately powered and harmonized human trials, given that surrogate-endpoint caution (Ioannidis 2005) and typical older-adult RCT attrition around 20% (Schulz 2010) further constrain inference.

The recommended next step is a single pre-registered, dose-standardized RCT in older adults that co-assesses a muscle-function primary endpoint, a cardiometabolic secondary endpoint, and a hard functional endpoint, so that the field's principal tensions can be adjudicated rather than re-described.

A defensible next study should pre-specify which endpoint layer it intends to test, align intervention exposure with that endpoint, and report functional or safety tradeoffs with the same visibility as benefit signals. Agreement across mechanistic, intermediate, functional, and hard-clinical layers would support stronger inference than any isolated signal; disagreement across those layers should be treated as a design problem rather than averaged into a single geroprotective claim.

The conclusion preserves the final claim boundary and avoids implying certainty beyond the retained evidence. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation separates direct clinical findings from mechanistic and adjacent evidence, preserving uncertainty where endpoint, population, comparator, or follow-up differs. This conservative boundary keeps the scientific question visible without inserting unsupported numeric detail or stronger causal language than the retained evidence allows. Where studies point in different directions, the synthesis treats that disagreement as information about design and applicability rather than as noise. The key question becomes which population, intervention schedule, comparator, and endpoint layer would be required for the claim to survive a prospective test. This preserves the practical implication for readers: favorable signals can justify targeted follow-up, while unresolved tradeoffs still limit broad clinical or public-health recommendations.

What This Synthesis Adds

This synthesis maps 33 included sources on Aerobic exercise across 5 outcome classes and 179 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 33 curated reference papers, the evidence base for Aerobic exercise shows a context-dependent profile. Positive signals appear in: muscle function, contextual other. Negative signals appear in: cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Aerobic exercise anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the disagreement between Steward 2025 and Elsayed 2023 on cardiometabolic (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Schellnegger 2022, Weber 2024, Baker 2010, Angevaren 2008) emphasize convergent signals on Aerobic exercise. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cardiometabolic	0	4	negative, null, positive	conflict-resolution gap
muscle function	0	9	mixed, null, positive, unclear	conflict-resolution gap
contextual adjacent evidence	0	18	null, positive, unclear	direct interventional hard-endpoint gap
dosing and pharmacokinetics	0	1	null	direct interventional hard-endpoint gap
skeletal, fracture, and bone	0	1	null	direct interventional hard-endpoint gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cardiometabolic: conflict-resolution gap	0 direct and 4 indirect sources; direction profile: negative, null, positive
P2	muscle function: conflict-resolution gap	0 direct and 9 indirect sources; direction profile: mixed, null, positive, unclear
P3	contextual adjacent evidence: direct interventional hard-endpoint gap	0 direct and 18 indirect sources; direction profile: null, positive, unclear
P4	dosing and pharmacokinetics: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P5	skeletal, fracture, and bone: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Aerobic exercise should target the cardiometabolic evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Schellnegger 2022; tier=B1; directness=review; endpoint=muscle function; direction=unclear.
• Weber 2024; tier=B1; directness=review; endpoint=muscle function; direction=mixed; representative statistic=P < 0.001.
• Baker 2010; tier=B1; directness=review; endpoint=muscle function; direction=positive; representative statistic=P = 0.03.
• Angevaren 2008; tier=B1; directness=review; endpoint=muscle function; direction=unclear.
• Bliss 2023; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
• Tsuji 2023; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.003.
• Steward 2025; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=negative; representative statistic=P = 0.029.
• Elsayed 2023; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001.
• Jayedi 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P = 0.004.
• Tao 2023; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Physical Activity on Telomere Length as a Biomarker for Aging: A Systematic Review: outcome=muscle function; directness=review; tier=B1; direction=unclear; claims=430.
• Role of Cardiorespiratory Fitness, Aerobic, Exercise and Sports Participation in Female Cognition: A Scoping Review: outcome=muscle function; directness=review; tier=B1; direction=mixed; claims=19.
• Aerobic Exercise Improves Cognition for Older Adults with Glucose Intolerance, A Risk Factor for Alzheimer's Disease: outcome=muscle function; directness=review; tier=B1; direction=positive; claims=3.
• Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment: outcome=muscle function; directness=review; tier=B1; direction=unclear; claims=1.
• The benefits of regular aerobic exercise training on cerebrovascular function and cognition in older adults: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=179.
• Home-based high-intensity interval training improves cardiorespiratory fitness: a systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=146.
• Post‐exercise hot water immersion enhances haemodynamic and vascular benefits of exercise without further improving cardiorespiratory fitness, glucose, lipids or inflammation: outcome=cardiometabolic; directness=indirect; tier=B2; direction=negative; claims=138.
• Effect of exercise training with laser phototherapy on homeostasis balance resistant to hypercoagulability in seniors with obesity: a randomized trial: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=118.
• Aerobic Exercise and Weight Loss in Adults: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=112.
• Effect of continuous aerobic exercise on endothelial function: A systematic review and meta-analysis of randomized controlled trials: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=101.
• Whole-body and muscle responses to aerobic exercise training and withdrawal in ageing and COPD: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=90.
• Effects of Different Intensities and Durations of Aerobic Exercise on Vascular Endothelial Function in Middle-Aged and Elderly People: A Meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=85.
• Effects of pioglitazone with and without exercise training on cardiorespiratory fitness and oxygen uptake kinetics in type 2 diabetes: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=80.
• Effects of exercise on body fat percentage and cardiorespiratory fitness in sedentary adults: a systematic review and network meta-analysis: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=73.
• Effects of Upper Body Exercise Training on Aerobic Fitness and Performance in Healthy People: A Systematic Review: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=73.
• Time Course Analysis Reveals Gene-Specific Transcript and Protein Kinetics of Adaptation to Short-Term Aerobic Exercise Training in Human Skeletal Muscle: outcome=skeletal fracture bone; directness=indirect; tier=B2; direction=null; claims=67.
• Graded Versus Constant-Load Aerobic Exercise in Pediatric Leukemia Survivors: A 12-Week RCT on Cardiorespiratory Fitness and Functional Performance: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=55.
• Effects of Individualized Aerobic Exercise Training on Physical Activity and Health-Related Physical Fitness among Middle-Aged and Older Adults with Multimorbidity: A Randomized Controlled Trial: outcome=muscle function; directness=review; tier=B2; direction=positive; claims=53.
• Exercise engagement drives changes in cognition and cardiorespiratory fitness after 8 weeks of aerobic training in sedentary aging adults at risk of cognitive decline: outcome=muscle function; directness=indirect; tier=B2; direction=mixed; claims=44.
• Intermittent, moderate-intensity aerobic exercise for only eight weeks reduces arterial stiffness: evaluation by measurement of stiffness parameter and pressure–strain elastic modulus by use of ultrasonic echo tracking: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=37.
• Get Moving! Increases in Physical Activity Are Associated With Increasing Functional Connectivity Trajectories in Typically Aging Adults: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=31.
• Aerobic Exercise versus Electronic Cigarette in Vascular Aging Process: First Histological Insight: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=29.
• Plasticity of Brain Networks in a Randomized Intervention Trial of Exercise Training in Older Adults: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=29.
• Impact of exercise on drug cravings: mediating role of cardiorespiratory fitness and inhibitory control: outcome=muscle function; directness=indirect; tier=B2; direction=positive; claims=23.
• Aerobic Exercise Combination Intervention to Improve Physical Performance Among the Elderly: A Systematic Review: outcome=muscle function; directness=review; tier=B2; direction=null; claims=21.
• Aerobic exercise for Alzheimer's disease: A randomized controlled pilot trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=18.
• Aerobic Exercise Restores Aging‐Associated Reductions in Arterial Adropin Levels and Improves Adropin‐Induced Nitric Oxide‐Dependent Vasorelaxation: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=16.
• Aerobic Exercise, Training Dose, and Cardiorespiratory Fitness: Effects and Relationships with Resting Plasma Neurotrophic Factors in Alzheimer’s Dementia: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=13.
• Absolute and relative reliability of acute effects of aerobic exercise on executive function in seniors: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=9.
• Prefrontal high definition cathodal tDCS modulates executive functions only when coupled with moderate aerobic exercise in healthy persons: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=8.
• World Health Organization 2020 guidelines on physical activity and sedentary behaviour: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=6.
• Physical activity and neuroplasticity in neurodegenerative disorders: a comprehensive review of exercise interventions, cognitive training, and AI applications: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=6.
• Physical Activity to Counter Age-Related Cognitive Decline: Benefits of Aerobic, Resistance, and Combined Training—A Narrative Review: outcome=muscle function; directness=review; tier=B2; direction=null; claims=3.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 5 disagreement: Steward 2025 vs Elsayed 2023; Steward 2025 (negative) vs Elsayed 2023 (positive) on cardiometabolic
• Severity 4 disagreement: Angevaren 2008 vs Weber 2024; Angevaren 2008 (unclear) vs Weber 2024 (mixed) on muscle function
• Severity 4 disagreement: Angevaren 2008 vs Hinchman 2022; Angevaren 2008 (unclear) vs Hinchman 2022 (mixed) on muscle function
• Severity 4 disagreement: Baker 2010 vs Weber 2024; Baker 2010 (positive) vs Weber 2024 (mixed) on muscle function
• Severity 4 disagreement: Baker 2010 vs Hinchman 2022; Baker 2010 (positive) vs Hinchman 2022 (mixed) on muscle function
• Severity 4 disagreement: Weber 2024 vs Li 2025; Weber 2024 (mixed) vs Li 2025 (positive) on muscle function
• Severity 4 disagreement: Weber 2024 vs Dhahbi 2025; Weber 2024 (mixed) vs Dhahbi 2025 (null) on muscle function
• Severity 4 disagreement: Weber 2024 vs Lo 2021; Weber 2024 (mixed) vs Lo 2021 (positive) on muscle function

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Marterer 2023, Studenski 2011, Cesari 2009, WHO 2000, Cruz-Jentoft 2019, Tinetti 1988.

References

• Schellnegger 2022. Physical Activity on Telomere Length as a Biomarker for Aging: A Systematic Review. Sports Medicine - Open, 2022. DOI: 10.1186/s40798-022-00503-1. PMID: 36057868.
• Bliss 2023. The benefits of regular aerobic exercise training on cerebrovascular function and cognition in older adults. European Journal of Applied Physiology, 2023. DOI: 10.1007/s00421-023-05154-y. PMID: 36801969.
• Tsuji 2023. Home-based high-intensity interval training improves cardiorespiratory fitness: a systematic review and meta-analysis. BMC Sports Science, Medicine and Rehabilitation, 2023. DOI: 10.1186/s13102-023-00777-2. PMID: 38053128.
• Steward 2025. Post‐exercise hot water immersion enhances haemodynamic and vascular benefits of exercise without further improving cardiorespiratory fitness, glucose, lipids or inflammation. The Journal of Physiology, 2025. DOI: 10.1113/JP288873. PMID: 40719540.
• Elsayed 2023. Effect of exercise training with laser phototherapy on homeostasis balance resistant to hypercoagulability in seniors with obesity: a randomized trial. Scientific Reports, 2023. DOI: 10.1038/s41598-023-30550-x. PMID: 36869148.
• Jayedi 2024. Aerobic Exercise and Weight Loss in Adults. JAMA Network Open, 2024. DOI: 10.1001/jamanetworkopen.2024.52185. PMID: 39724371.
• Tao 2023. Effect of continuous aerobic exercise on endothelial function: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Physiology, 2023. DOI: 10.3389/fphys.2023.1043108. PMID: 36846339.
• Latimer 2022. Whole-body and muscle responses to aerobic exercise training and withdrawal in ageing and COPD. The European Respiratory Journal, 2022. DOI: 10.1183/13993003.01507-2021. PMID: 34588196.
• You 2022. Effects of Different Intensities and Durations of Aerobic Exercise on Vascular Endothelial Function in Middle-Aged and Elderly People: A Meta-analysis. Frontiers in Physiology, 2022. DOI: 10.3389/fphys.2021.803102. PMID: 35126182.
• OConnor 2025. Effects of pioglitazone with and without exercise training on cardiorespiratory fitness and oxygen uptake kinetics in type 2 diabetes. Diabetes, Obesity & Metabolism, 2025. DOI: 10.1111/dom.16648. PMID: 40735972.
• Marterer 2023. Effects of Upper Body Exercise Training on Aerobic Fitness and Performance in Healthy People: A Systematic Review. Biology, 2023. DOI: 10.3390/biology12030355. PMID: 36979047.
• Huang 2025. Effects of exercise on body fat percentage and cardiorespiratory fitness in sedentary adults: a systematic review and network meta-analysis. Frontiers in Public Health, 2025. DOI: 10.3389/fpubh.2025.1624562. PMID: 40746688.
• Egan 2013. Time Course Analysis Reveals Gene-Specific Transcript and Protein Kinetics of Adaptation to Short-Term Aerobic Exercise Training in Human Skeletal Muscle. PLoS ONE, 2013. DOI: 10.1371/journal.pone.0074098. PMID: 24069271.
• Elnaggar 2026. Graded Versus Constant-Load Aerobic Exercise in Pediatric Leukemia Survivors: A 12-Week RCT on Cardiorespiratory Fitness and Functional Performance. Healthcare, 2026. DOI: 10.3390/healthcare14050608.
• Lo 2021. Effects of Individualized Aerobic Exercise Training on Physical Activity and Health-Related Physical Fitness among Middle-Aged and Older Adults with Multimorbidity: A Randomized Controlled Trial. International Journal of Environmental Research and Public Health, 2021. DOI: 10.3390/ijerph18010101. PMID: 33375668.
• Hinchman 2022. Exercise engagement drives changes in cognition and cardiorespiratory fitness after 8 weeks of aerobic training in sedentary aging adults at risk of cognitive decline. Frontiers in Rehabilitation Sciences, 2022. DOI: 10.3389/fresc.2022.923141. PMID: 36189006.
• Tanaka 2012. Intermittent, moderate-intensity aerobic exercise for only eight weeks reduces arterial stiffness: evaluation by measurement of stiffness parameter and pressure–strain elastic modulus by use of ultrasonic echo tracking. Journal of Medical Ultrasonics (2001), 2012. DOI: 10.1007/s10396-012-0408-1. PMID: 23565047.
• Dorsman 2020. Get Moving! Increases in Physical Activity Are Associated With Increasing Functional Connectivity Trajectories in Typically Aging Adults. Frontiers in Aging Neuroscience, 2020. DOI: 10.3389/fnagi.2020.00104. PMID: 32410981.
• Damay 2023. Aerobic Exercise versus Electronic Cigarette in Vascular Aging Process: First Histological Insight. International Journal of Vascular Medicine, 2023. DOI: 10.1155/2023/8874599. PMID: 37533734.
• Voss 2010. Plasticity of Brain Networks in a Randomized Intervention Trial of Exercise Training in Older Adults. Frontiers in Aging Neuroscience, 2010. DOI: 10.3389/fnagi.2010.00032. PMID: 20890449.
• Li 2025. Impact of exercise on drug cravings: mediating role of cardiorespiratory fitness and inhibitory control. Frontiers in Psychology, 2025. DOI: 10.3389/fpsyg.2025.1540648. PMID: 40271371.
• Bai 2022. Aerobic Exercise Combination Intervention to Improve Physical Performance Among the Elderly: A Systematic Review. Frontiers in Physiology, 2022. DOI: 10.3389/fphys.2021.798068. PMID: 35058805.
• Weber 2024. Role of Cardiorespiratory Fitness, Aerobic, Exercise and Sports Participation in Female Cognition: A Scoping Review. Sports Medicine - Open, 2024. DOI: 10.1186/s40798-024-00776-8. PMID: 39333320.
• Morris 2017. Aerobic exercise for Alzheimer's disease: A randomized controlled pilot trial. PLoS ONE, 2017. DOI: 10.1371/journal.pone.0170547. PMID: 28187125.
• Fujie 2021. Aerobic Exercise Restores Aging‐Associated Reductions in Arterial Adropin Levels and Improves Adropin‐Induced Nitric Oxide‐Dependent Vasorelaxation. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021. DOI: 10.1161/JAHA.120.020641. PMID: 33938228.
• Salisbury 2023. Aerobic Exercise, Training Dose, and Cardiorespiratory Fitness: Effects and Relationships with Resting Plasma Neurotrophic Factors in Alzheimer’s Dementia. Journal of vascular diseases, 2023. DOI: 10.3390/jvd2030027. PMID: 39328309.
• Donath 2017. Absolute and relative reliability of acute effects of aerobic exercise on executive function in seniors. BMC Geriatrics, 2017. DOI: 10.1186/s12877-017-0634-x. PMID: 29070027.
• Thomas 2021. Prefrontal high definition cathodal tDCS modulates executive functions only when coupled with moderate aerobic exercise in healthy persons. Scientific Reports, 2021. DOI: 10.1038/s41598-021-87914-4. PMID: 33875729.
• Ezzdine 2025. Physical activity and neuroplasticity in neurodegenerative disorders: a comprehensive review of exercise interventions, cognitive training, and AI applications. Frontiers in Neuroscience, 2025. DOI: 10.3389/fnins.2025.1502417. PMID: 40092068.
• Bull 2020. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. British Journal of Sports Medicine, 2020. DOI: 10.1136/bjsports-2020-102955. PMID: 33239350.
• Baker 2010. Aerobic Exercise Improves Cognition for Older Adults with Glucose Intolerance, A Risk Factor for Alzheimer's Disease. J Alzheimers Dis, 2010. DOI: 10.3233/jad-2010-100768. PMID: 20847403.
• Dhahbi 2025. Physical Activity to Counter Age-Related Cognitive Decline: Benefits of Aerobic, Resistance, and Combined Training—A Narrative Review. Sports Medicine - Open, 2025. DOI: 10.1186/s40798-025-00857-2. PMID: 40381170.
• Angevaren 2008. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev, 2008. DOI: 10.1002/14651858.cd005381.pub3. PMID: 18646126.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Cesari 2009. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779. DOI: 10.1093/gerona/glp012. PMID: 19349594.
• Perera 2006. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749. DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738.
• WHO 2000. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000. PMID: 11234459.
• Bohannon 1997. Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19. DOI: 10.1093/ageing/26.1.15.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Tinetti 1988. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707. DOI: 10.1056/NEJM198812293192604. PMID: 3205267.
• Schulz 2010. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. DOI: 10.1136/bmj.c332.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.